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ABSTRACT
Introduction: This study assessed the relative
importance of treatment-related attributes in
influencing patient preferences for glucagon-
like peptide-1 receptor agonists (GLP-1RAs)
among injection-experienced type 2 diabetes
mellitus (T2DM) patients in Germany and the
United Kingdom.
Methods: T2DM patients experienced with
injecting once-weekly (QW) exenatide or
once-daily (QD) liraglutide completed an online
discrete-choice experiment (DCE) survey.
Patients chose between hypothetical blinded
treatment profiles reflecting attributes of
GLP-1RAs. The DCE survey included eight
attributes: efficacy, side effects, device size,
needle size, titration, injection preparation,
long-term efficacy/safety, and dosing frequency.
Odds ratios (ORs) and 95% confidence intervals
(CIs) were calculated using a conditional logit
model indicating the likelihood of choosing a
treatment with a given attribute level versus a
reference attribute level.
Results: 510 GLP-1RA injection-experienced
patients completed the survey; 45.3% respon-
dents were being treated with exenatide QW
and 54.7% respondents were being treated with
liraglutide QD. In terms of GLP-1RA attributes,
patients indicated a preference for a treatment
with greater efficacy (i.e., a 1.5-point improve-
ment in HbA1c) (OR 2.58; 95% CI 2.37, 2.80;
p\0.001), fewer side effects (OR 2.67; 95% CI
2.52, 2.82; p\0.001), once-weekly rather than
once-daily administration (OR 2.26; 95% CI
2.13, 2.39; p\0.001), and the preparation
required for a multi-use pen (OR 1.71; 95% CI
1.55, 1.88; p\0.001). Needle size, device size,
and titration were not significant drivers of
patient preference.
Conclusions: Among GLP-1RA injection-expe-
rienced patients, key drivers of treatment pref-
erence for a hypothetical GLP-RA profile were
side effects, efficacy, dosing frequency, and
required preparation. Understanding patient
preferences is important for optimizing treat-
ment decision-making and improving treat-
ment adherence.
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INTRODUCTION
The global prevalence of diabetes has been
steadily increasing for the last 30 years [1–3]. In
2015, 415 million people were estimated to
have diabetes across the globe [4]. By 2040, this
number is expected to increase to 642 million
[4]. The highest national prevalence rates of
diabetes are found in countries in Oceania, fol-
lowed by the Middle East and North Africa [1].
In these regions, the prevalence of diabetes is
five to ten times higher than the lowest preva-
lence rates found in some Western European
countries. Nevertheless, even in Western Euro-
pean countries, diabetes has become increas-
ingly prevalent [1]. Studies have indicated an
increase in prevalence from 2.39% in 2000 to
5.32% in 2013 in the United Kingdom (UK) [5],
from 6.6% in 2007 to 8.6% in 2010 in south-
western Germany [6], and from 2.8% in 1990 to
4.6% in 2010 in Stockholm, Sweden [7]. In
high-income countries, approximately 87–91%
of diabetes patients have type 2 diabetes melli-
tus (T2DM) [3, 4], so the increases seen in the
prevalence of diabetes are likely to be due to the
increase in T2DM [1].
A patient-centered approach to the treat-
ment of T2DM is advised [8–10], with the
choice of diabetes therapy being based on
attributes specific to both patients and the
medication. Such an approach balances the
benefits of glycemic control against the poten-
tial risks (e.g., weight gain, hypoglycemia, cost)
of any medication, while also taking into
account factors relevant to the patient (e.g., age,
health status, preferences, therapeutic goal, and
likely adherence) [8–12].
Glucagon-like peptide-1 receptor agonists
(GLP-1RAs) are one of the options recom-
mended for the treatment of T2DM [8–10].
GLP-1RAs mimic GLP-1, a gut-derived incretin
hormone which increases insulin secretion,
inhibits glucagon secretion, increases satiety,
and slows gastric emptying [13–15]. These
agents reduce fasting and postprandial glucose
and glycated hemoglobin A1c (HbA1c) levels
but are associated with a low risk of hypo-
glycemia because they act in a glucose-depen-
dent manner [15, 16]. Their use has also been
associated with bodyweight reduction. The
GLP-1RAs differ in their molecular structure and
degree of homology to endogenous GLP-1 [17],
and therefore some variations in their effects on
glycemic control and side effects have been
reported [15, 17, 18]. The GLP-1RAs also differ
in their frequency of dosing and types of
delivery systems.
Given the differences between the GLP-1RAs,
it is important to understand patients’ prefer-
ences for the clinical and nonclinical features of
these agents. Such an understanding is impor-
tant given the high level of non-adherence to
T2DM medication [19–24], and the consequent
compromise in outcomes [20, 25, 26]. If clinical
decisions take into consideration patient pref-
erence, this is likely to be reflected in greater
adherence to treatment and improved clinical
outcomes [9, 27].
Discrete-choice experiments (DCEs) have
been used to quantify patients’ preferences for
the various attributes of diabetes treatments
[28–35]. A DCE can provide useful information
regarding patients’ preferences when they are
making very specific medication choices. Previ-
ous DCE studies have investigated the attributes
of GLP-1RAs, including efficacy (percentage of
patients who reach their HbA1c goals) and tol-
erability (weight gain, nausea, and hypo-
glycemia), as well as injection-related features
such as type of injection device or injection fre-
quency [30, 31, 33]. Further investigation is
warranted to gain insight into other attributes
(such as device size, preparation required to
deliver the medication, requirement for titra-
tion, and evidence for long-term efficacy and
safety) that may be influencing patients’ prefer-
ences for one GLP-1RA over another.
The objective of this study was to assess the
relative importance of treatment-related attri-
butes in influencing preferences for GLP-1RAs
among GLP-1RA injection-experienced patients
with T2DM in Germany and the United King-
dom (UK). Two commonly prescribed GLP-1RAs
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[once-weekly (QW) exenatide and once-daily
(QD) liraglutide] were chosen to represent




This was a two-stage descriptive study that
included an initial survey development phase
(in both injection-naı¨ve and injection-experi-
enced T2DM patients), followed by a second
phase involving a one-time, web-based mul-
ti-country DCE survey involving hypothetical
treatment profiles, in GLP-1 RA injection-expe-
rienced T2DM patients (reported here) and in
injection-naı¨ve T2DM patients (reported else-
where [36]).
The DCE survey was developed in line with
best practice guidance [37, 38]. Using this
approach, the key characteristics (attributes) of
alternative treatments are identified and a series
of levels for each attribute are then selected.
Participants are then asked to choose from sev-
eral hypothetical options, each of which details
a series of attributes at different levels. This
approach can provide information about the
relative importance of the attributes to the
patients and their willingness to accept trade-
offs between the different attributes.
The survey was programmed and hosted by
Global Perspectives (Berkshire, UK) on a secure
server. Eligible participants were identified by a
research recruitment agency using multiple
methods including reviewing patient databases
of those agreeable to contact for research study
participation, encouraging referrals from clini-
cians and patient associations, and advertising
in targeted publications. All eligible patients
provided online consent through the web link
prior to completing the survey. Patients who
completed the survey received compensation
for their participation.
The study protocol was approved by the Salus
Institutional Review Board (Austin, TX, USA). All
procedures followedwere in accordancewith the
ethical standards of the responsible committee
on human experimentation (institutional and
national) and with the Helsinki Declaration of
1964, as revised in 2013. Informed consent was
obtained from all patients before they were
included in the study.
Phase One: Survey Development Stage
A literature review and qualitative research with
T2DMpatientswere conducted to informattribute
selection and survey development. Identification
of the key attributes of GLP-1RAs were based on
open-ended, one-on-one qualitative interviews
conducted with fifty T2DM patients from five
countries (Brazil, China, Germany, Japan, and the
UK) to identify and examine treatment attributes
important to T2DM patients [39].
Eight attributes of GLP-1RAs were chosen for
inclusion in a draft DCE survey: common
GLP-1RA side effects, dosing frequency,
required injection preparation, improvement in
HbA1c, requirement for titration, evidence of
long-term efficacy/safety [40], injection device
size, and needle size. The US Food and Drug
Administration-approved labels of two com-
mon GLP-1RAs (exenatide QW and liraglutide
QD) were reviewed to provide hypothetical
base-case treatment profiles [41, 42].
One treatment was a profile of a daily
injectable approximating-liraglutide QD. The
other treatment was a weekly injectable ap-
proximating-exenatide QW. Exenatide QW is
delivered once-weekly, does not require titra-
tion, and uses a thicker, longer needle. Delivery
of exenatide was specified as either using a sin-
gle-use pen device or via an auto-injector. The
single-use pen device contains exenatide
microspheres and aqueous-based diluent in
separate chambers, requiring careful prepara-
tion of the medication, while the auto-injector
has the exenatide microspheres and lipid-based
diluent prefilled in one chamber (see Fig. S1 in
the Electronic supplementary material, ESM, for
details). Exenatide QW can also be delivered in
a single-dose tray (vial and syringe). Liraglutide
QD is delivered once-daily via a multiple-use
pen, requires careful preparation and titration
of the medication (see Fig. S1 in the ESM for
details), and uses a thinner, shorter needle.
Further details of the attributes and the levels
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assigned to each potential attribute are shown
in Table 1.
The attributes and levels were combined into
choice sets using a published orthogonal array
[43]. An orthogonal fractional factorial design
was used to identify the minimum specification
of the combinations of attributes and levels that
could define the hypothetical treatments [43].
The combinations were then paired using a
fold-over design [44]. Each choice question
presented two hypothetical treatments (treat-
ment A or B) that reflected attributes associated
Table 1 Attributes and levels included in the discrete-choice experiment survey
Attribute Levels
Side effects Side-effects proﬁle B: 21% chance of nausea, 13% chance of diarrhea, 11% chance of vomiting,
and 1% chance of injection-site nodules (reference)b
Side-effects proﬁle A: 9% chance of nausea, 6% chance of diarrhea, 4% chance of vomiting,
and 10% chance of injection-site nodulesa
Dosing frequency Once a day (reference)b
Once a weeka




Improvement in HbA1c 0.8-point improvement in HbA1c (reference)
1.2-point improvement in HbA1ca,b
1.5-point improvement in HbA1c
Titration Requires titration (reference)b










Needle size Longer and thicker (reference)a
Shorter and thinnerb
HbA1c glycated hemoglobin, QD once-daily, QW once-weekly
a Attribute associated with exenatide QW; delivery of exenatide QW is achieved using either a single-use pen or an
auto-injecting single-use device containing exenatide microspheres and diluent preﬁlled into separate chambers
b Attribute associated with liraglutide QD
338 Diabetes Ther (2017) 8:335–353
with exenatide QW and liraglutide QD. A total
of 32 pairs of choice sets were generated, with
each respondent being presented with a set of
16 unique paired choice sets [45]. An example of
a choice set included in the survey is provided
in Fig. 1.
Fig. 1 Example of a discrete-choice experiment question comparing treatment proﬁles reﬂecting liraglutide QD and
exenatide QW (treatment A vs. treatment B)
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The English-language survey was pilot-tested
with respect to wording and comprehension as
well as cognitive and overall burden with five
T2DM patients in the UK. Revisions were made
to improve clarity. The survey was then trans-
lated into German and reviewed with respect to
wording and comprehension by two indepen-
dent native German speakers so that it could be
used in Germany.
Phase Two: Web-Based DCE Study
In the second phase of the study, GLP-1RA
injection-experienced patients from the UK and
Germany completed the one-time, web-based
survey. Only patients from the UK and Ger-
many were included, as GLP-1RAs were not
readily available in the other countries at the
time of the study inception. Interested partici-
pants were provided with an internet link to the
online web-based DCE survey.
The survey included screening questions and
questions relating to past and current medica-
tion use, adherence, clinical history, and
demographic information. The adherence
questions asked about frequency of missing,
skipping, or being late in taking their injected
GLP-1RA, and what aspect of their current
medication made it most difficult or inconve-
nient to take as prescribed. In addition, partic-
ipants were asked hypothetical questions about
the potential impact of dosing frequency on
their adherence.
The second section of the survey included
the DCE questions. The DCE began by present-
ing participants with descriptions of the attri-
butes and the levels included in the survey,
followed by the 16 paired comparison
questions.
Survey Participants
In the second phase of the study, the DCE sur-
vey was completed by T2DM patients from the
UK and Germany who were currently using
GLP-1RA injections (exenatide QW or liraglu-
tide QD) for more than 2 months prior to
screening (i.e., GLP-1RA injection-experienced).
Other eligibility criteria included: age 18 years
or older; adequate written and oral fluency in
the target language; be willing and able to
complete a 30-min online survey about treat-
ment experiences and preferences; have access
to the Internet; and be willing to provide
informed consent. Patients with type 1 diabetes
mellitus, who were pregnant, or who were cur-
rently on insulin therapy were excluded from
the survey.
Data Analyses
SAS statistical software, version 4.3 (SAS Insti-
tute Inc., Cary, NC, USA) was used to conduct
the analyses. Descriptive statistics [means,
standard deviations (SD), ranges, frequencies,
and percentages] were reported for the demo-
graphic and clinical characteristics data and the
self-reported data on adherence to medication.
The DCE responses were analyzed using a con-
ditional or mixed logit model, with each attri-
bute and level included as a separate variable in
the model. The choice of treatment was the
dependent variable and was analyzed condi-
tionally for each choice set (i.e., each treatment
choice the respondent had to make). The con-
ditional logit model provided regression coeffi-
cients (i.e., utility estimates), which were then
presented as odds ratios (ORs) and 95% confi-
dence intervals (CI). High ORs indicated a
strong preference for that attribute level versus a
reference attribute level. All analyses were per-
formed for the total sample and separately for
each country.
Sensitivity analyses were conducted to
examine how much a product’s overall prefer-
ence was improved or worsened by changing
certain attributes while holding all other attri-
butes at constant base case levels. For example,
the exenatide QW profile was compared to the
liraglutide QD profile, assuming better efficacy
for liraglutide QD versus exenatide QW. The
exenatide QW profile assuming an auto-injector
device size and auto-injector preparation was
also compared to the liraglutide QD profile.
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RESULTS
Sample Characteristics
A total of 510 GLP-1RA injection-experienced
patients completed the survey (Table 2). The
mean age of the patients in the study was
57.0 years, and 51.4% were male. The majority
was Caucasian, employed, and had some formal
education (Table 2). On average, the duration of
the T2DM of the participants was 7.2 years.
Current Treatments
For their clinical care, 45.3% respondents were
receiving treatment with exenatide QW and
54.7% respondents were treated with liraglutide
QW, using a vial and syringe (10.8%), dispos-
able single-use pen (40.6%), or a disposable
multiple-use pen (48.6%). Of the injection-ex-
perienced patients, 17.5% were using one
medication only, 56.9% were using two medi-
cations, and 25.7% were using three or more
medications. The majority of participants were
also using metformin to treat their diabetes
(64.5%). The sociodemographic and clinical
characteristics were generally similar between
patients from the UK and Germany (Table 2).
Overall, 52.2% of respondents indicated
that they never missed a dose of their
injectable medication. More of the patients who
were treated with liraglutide QD (53.8%) than
exenatide QW (40.7%) reported missing a dose
(Fig. 2). The percentages of the exenatide QW
and liraglutide QD recipients who missed a dose
at least once a month were 3.9% and 20.1%,
respectively.
The top reasons for patients missing an
injection included forgetting (75.1%), not hav-
ing the medication with them at the scheduled
time (29.8%), a change in daily routine (29.0%),
not taking the medication out of the refrigera-
tor at the scheduled time (28.6%), and running
out of medication (18.0%). More than half
(59.4%) reported taking medication late, with
the reasons including forgetting (59.1%), not
taking the medication out of the refrigerator at
the scheduled time (37.3%), experiencing a
change in daily routine (35.3%), or not having
the medication with them at the scheduled
time (30.7%). When patients were asked about
hypothetical injectable T2DM treatments,
72.0% of respondents (92.2% exenatide and
55.2% liraglutide) stated that a once-weekly
dose would be easiest to follow, while 27.1% of
respondents (6.1% exenatide and 44.4%
liraglutide recipients) selected a once-daily
injection, and 1.0% of all respondents thought




Side effects, efficacy, dosing frequency, and
required preparation were the four most
important attributes influencing patient prefer-
ence for an injectable GLP-1RA medication,
according to analyses pooled from both coun-
tries and from country-specific data from the
UK or Germany (Table 3). Across both coun-
tries, patients indicated a preference for a
treatment associated with fewer side effects (i.e.,
less nausea, diarrhea, vomiting, or injection-site
nodules), a treatment offering greater efficacy
(i.e., a 1.5-point improvement in HbA1c), a
treatment that was administered once-weekly,
and the preparation required for a multi-use
pen. German respondents indicated that greater
efficacy (i.e., a 1.5-point improvement in
HbA1c) was the most valued attribute, followed
by side effects, dosing frequency, and required
preparation. The UK respondents indicated the
level of side effects to be the most important
influence on their preference for a treatment,
followed by efficacy, preparation required, and
dosing frequency (Table 3).
In terms of the five device-related attributes,
dosing frequency and the preparation required
were significant predictors of patient preference
according to the pooled and country-specific
outcomes. As mentioned above, patients pre-
ferred weekly to daily dosing (Table 3). Patients
indicated a preference for the preparation
required for a multi-use pen and an auto-injec-
tor to that of a vial and syringe, according to
pooled data from both countries. Needle size,
device size, and titration were not significant
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Table 2 Self-reported sociodemographic and clinical characteristics of injection-experienced type 2 diabetes mellitus
participants
Patient characteristic Total (N5 510) UK (n 5 220) Germany (n5 290)
Mean age (SD), years [range] 57.0 (11.0) [20.0, 81.0] 53.0 (11.5) [20.0–76.0] 60.0 (9.6) [31.0–81.0]
Male, n (%) 262 (51.4) 118 (53.6) 144 (49.7)
Female, n (%) 248 (48.6) 102 (46.4) 146 (50.3)
Race/ethnicity, n (%)
Caucasian 477 (93.5) 207 (94.1) 270 (93.1)
Mixed/multiple ethnic groups 4 (0.8) 1 (0.5) 3 (1.0)
Asian/Asian British 17 (3.3) 6 (2.7) 11 (3.8)
Black/African/Caribbean/Black British 8 (1.6) 5 (2.3) 3 (1.0)
Other 5 (1.0) 0 (0.0) 4 (1.4)
Employment status, n (%)
Employed, full-time 180 (35.3) 81 (36.8) 99 (34.1)
Employed, part-time 66 (12.9) 25 (11.4) 41 (14.1)
Self-employed 26 (5.1) 13 (5.9) 13 (4.5)
Stay-at-home parent/homemaker 21 (4.1) 8 (3.6) 13 (4.5)
Unemployed 23 (4.5) 14 (6.4) 9 (3.1)
Retired 159 (31.2) 46 (20.9) 113 (39.0)
Disabled 32 (6.3) 30 (13.6) 2 (0.7)
Other 3 (0.6) 3 (1.4) 0 (0.0)
Education, n (%)
No formal qualiﬁcations 48 (9.4) 19 (8.6) 29 (10.0)
GCSE/O-level or equivalent 224 (43.9) 66 (30.0) 158 (54.5)
A-level or equivalent 126 (24.7) 56 (25.5) 70 (24.1)
University degree 83 (16.3) 55 (25.0) 28 (9.7)
Postgraduate degree 29 (5.7) 24 (10.9) 5 (1.7)
Mean weight, kg (SD) 101.7 (23.7) 108.0 (28.0) 96.9 (18.4)
Mean height, m (SD) 1.7 (0.1) 1.7 (0.1) 1.7 (0.1)
Mean BMI (kg/m2), (SD) 34.2 (7.5) 36.7 (9.2) 32.3 (5.1)
Mean duration of T2DM, years (SD) 7.2 (5.9) 9.9 (7.1) 5.1 (3.6)
Mean HbA1c (SD), %
a 7.4 (1.9) 7.9 (2.9) 7.1 (0.7)
Current GLP-1RA treatment
Exenatide QW, n (%) 231 (45.3) 84 (38.2) 147 (50.7)
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drivers of patient preference, according to
analysis of the pooled outcomes (Table 3).
Comparison of Hypothetical GLP-1RA
Profiles
Hypothetical profiles similar to commonly pre-
scribed GLP-1RAs with important differences in
attributes were examined. Pooled data showed
that when efficacy was assumed to be equal
(1.2-point reduction in HbA1c) for both hypo-
thetical treatment profiles, more injection-expe-
rienced patients preferred a GLP-1RA profile
approximating exenatide QW administered via a
single-use pen over a profile approximating
liraglutide QD (Table 4). When examined by
country, preference for exenatide QW (single-use
pen) was higher among the German respondents
than the respondents from the UK (Table 4).
Even when the efficacy was assumed to be better
for liraglutide QD (1.2-point reduction in
HbA1c) than for single-use pen exenatide QW
(0.8-point reduction in HbA1C), more respon-
dents preferred the profile approximating exe-
natide QW (single-use pen) than the liraglutide
profile, according to the pooled data from both
countries (31.8% vs. 68.2%; OR 2.15; p\0.001),
the UK respondents only (38.5% vs. 61.5%; OR
1.60; p\0.001), and the German respondents
only (25.6% vs. 74.4%; OR 2.91; p\0.001).
Table 2 continued
Patient characteristic Total (N5 510) UK (n 5 220) Germany (n5 290)
Liraglutide QD, n (%) 279 (54.7) 136 (61.8) 143 (49.3)
BMI body mass index, GLP-1RA glucagon-like peptide-1 receptor agonist, HbA1c hemoglobin A1c, QD once-daily, QW
once-weekly, SD standard deviation, T2DM type 2 diabetes mellitus
a n = 109 (UK) and 198 (Germany)
Fig. 2 Frequency of missing an injection of GLP-1 RA in injection-experienced patients with type 2 diabetes mellitus


























































































































































































































































































































































































































































































































































































































































































































344 Diabetes Ther (2017) 8:335–353
Changing device type from a single-use pen
to an auto-injector pen, and assuming equal
efficacy between the hypothetical profiles,
increased the strength of preference for the
profile approximating exenatide QW compared
with a profile approximating liraglutide QD,
according to an analysis across both countries
(Table 5). When examined by country, prefer-
ence for exenatide QW (auto-injector) was
higher among the German respondents than
the UK respondents (Table 5). When efficacy
was assumed to be better for liraglutide QD
(1.2-point improvement in HbA1c) than for
exenatide QW (0.8-point improvement in
HbA1C), pooled results continued to show a
higher preference for the profile approximating
exenatide QW (auto-injector) over the profile
approximating liraglutide QD (OR 4.00,
p\0.001). When examined by country, the
preference was higher among German respon-
dents (OR 4.59; p\0.001) than among the UK
respondents (OR 3.68; p\0.001).
DISCUSSION
This DCE study, based on hypothetical treat-
ment profiles, assessed the relative importance
of treatment-related attributes in influencing
preferences for GLP-1RAs among GLP-1RA
injection-experienced patients with T2DM from
Germany and the UK. Hypothetical treatment
profiles were constructed based on attributes
from two GLP-1RAs with important differences
in attributes (i.e., exenatide QW and liraglutide
QD) that were commonly used in these two
countries. Across both countries, patients iden-
tified the top four most important attributes as
being efficacy, side effects, dosing frequency,
and required preparation. When device-related
attributes were specifically examined, dosing
frequency and the preparation required were
significant predictors of patient preference.
Needle size, device size, and titration were not
significant drivers of preference for injec-
tion-experienced patients.
Other DCE studies have also examined
patients’ preferences for efficacy, side effects,
and device-related attributes of GLP-1RAs in
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Japan [30]. Another US study in injection-ex-
perienced and injection-naı¨ve T2DM patients
focused on preferences for different dosing and
device-related attributes of GLP-1RAs [33].
However, comparison of the current study with
other GLP-1RA preference studies [30, 31, 33] is
problematic given that many of the attributes
(e.g., side effects and efficacy) were defined dif-
ferently across studies. Nevertheless, outcomes
from these studies provide an important con-
text for assessing the influence of injected
GLP-1RA attributes on patients’ preferences. As
with the current study, these studies indicated
that while efficacy and tolerability attributes
were important influencers of patient prefer-
ence, other dosing and device-related attributes
were also important [30, 31, 33].
This study in injection-experienced patients,
along with a study with a similar design in
injection-naı¨ve patients [36], sought to deter-
mine if other attributes of medication (e.g.,
device size, the preparation required to deliver
the medication, the needle size, the require-
ment for titration, and the evidence for long-
term efficacy and safety) were also influential in
determining patients’ preferences. The out-
comes from both of these studies were similar,
with both studies indicating that side effects,
efficacy, and dosing frequency were among the
most important treatment attributes while
needle size and device size were among the least
important predictors of patient preference.
However, preparation required was among the
least important attributes for the injec-
tion-naı¨ve sample, while it was an important
driver of preference in the injection-experi-
enced sample. The opposite was true for titra-
tion, which was a significant predictor of choice
among the injection-naı¨ve patients but was not
so for injection-experienced patients.
Dosing frequency was an important driver of
patient preference across all studies, including
the current study [30, 31, 33]. Dosing frequency
was the most influential attribute of GLP-1RA
medication in the DCE study conducted in the
US that only focused on device-related attri-
butes in injection-experienced and injec-
tion-naı¨ve patients [33]. The DCE studies
conducted in Japan and the UK in injec-
tion-naı¨ve patients also found that dosing
frequency was among the top attributes influ-
encing patient preference for GLP-1RAs [30, 31].
In all the GLP-1RA studies, a once-weekly dos-
ing regimen was consistently preferred over a
once-daily dosing regimen [30, 31, 36, 37, 46,
47]. Interestingly, DCE studies in patients with
another chronic disease (multiple sclerosis; MS)
also found that the frequency of injections was
an important driver of preference for
injectable MS treatments [48, 49].
Preparation of the GLP-1RA medication was
an important aspect influencing patient prefer-
ence according to outcomes from the current
study. Similarly, a DCE study in patients with
multiple sclerosis (MS) found that ease of use of
an injection device (no need for assembly or
drug reconstitution) was an important driver of
treatment preferences [50].
Efficacy is ranked highly among T2DM
patient preferences; however, it may not be the
most important influencer of patient preference
when deciding between medications that have
very similar efficacies. Various studies have
demonstrated equivalent efficacies of
GLP-1RAs. For example, in a real-world study,
changes in HbA1c were similar for those
receiving exenatide QW and those receiving
liraglutide QD over a 12-month period [51].
Similarly, a systematic review of 22 studies
indicated that there was no difference between
the two GLP-1RAs with regard to the level of
control of HbA1c levels [52]. In this study, when
efficacy was assumed to be equal between two
hypothetical profiles, patients from both coun-
tries favored a GLP-1RA profile approximating
exenatide QW (delivered via either a single-use
pen or auto-injector) over a GLP-1RA profile
approximating liraglutide QD. Similarly, injec-
tion-naı¨ve T2DM patients from both countries
indicated a strong preference for a GLP-1RA
profile approximating exenatide QW (delivered
via either a single-use pen or auto-injector) over
a profile approximating liraglutide QD [36].
Even when the efficacies of the GLP-1RAs are
not equal, patient preference for other attri-
butes of the medication may be an important
consideration. As demonstrated in this study of
injection-experienced patients and in the study
of injection-naı¨ve patients [36], when the pro-
file approximating liraglutide QD was assumed
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to have better efficacy (1.2-point vs. 0.8-point
improvement in HbA1c, respectively), patients
still favored the profile approximating exe-
natide QW. Thus, these results indicate that
attributes other than efficacy influenced patient
preference for a hypothetical GLP-1RA profile.
Improvements in adherence are more likely
to occur if patients’ preferences for the attri-
butes of T2DM medication are considered when
clinical decisions are being made [9, 10, 27]. If
patients’ adherence to medication for T2DM
can be improved, then improvements in dia-
betes-related outcomes are likely to occur,
including improved glycemic control, reduced
diabetes-related complications, and decreased
healthcare resource utilization [20, 25, 26,
53–55].
Notably, once-weekly injections of a
GLP-1RA have been associated with improved
adherence compared with once-daily injections
of a GLP-1RA [46, 56]. Outcomes from this
global study confirmed these findings, with
fewer of the patients treated with exenatide QW
than those treated with liraglutide QD reporting
missing doses of their medication. Potentially,
omitting a single dose of a once-weekly
injectable medication such as exenatide may
not have a such a significant impact on overall
blood glucose, given that a once-weekly injec-
tion of exenatide provides a constant 24-h
exposure to the drug that is associated with
improvement in HbA1c, fasting blood glucose,
and postprandial hyperglycemia [57–59].
Moreover, after treatment cessation, plasma
exenatide levels do not decrease to below those
considered to have a therapeutic effect until
after about 6 weeks. In contrast, continuous
injections of liraglutide QD are required to
maintain a constant 24-h exposure to the drug
that result in the control of blood glucose levels
[60]. Thus, missing a daily injection may have a
more pronounced effect on blood glucose levels
and overall glycemic control. However, these
suppositions are yet to be confirmed in clinical
studies.
A patient-centered approach that takes into
account patients’ preferences is needed not only
during the clinical decisions that involve
patients with T2DM [8–10] but also during the
development of any diabetes medication,
including GLP1-RAs. During the development
process, injectable GLP-1RAs have improved
from twice-daily injections (e.g., exenatide) to
once-daily injections (e.g., liraglutide, lixisen-
atide), and now to once-weekly formulations
(e.g., exenatide, albiglutide, and dulaglutide).
Other patient-centered improvements in
injectable medication involve the development
of pen devices, allowing quicker, easier, and
more convenient delivery. In this study, it was
not surprising that hypothetical GLP-1RA pro-
files including a vial and syringe were the least
favored, while hypothetical profiles involving
pens were more highly favored.
There were some limitations in the design of
this study. DCEs may not accurately reflect
real-world decisions. Due to the recruitment
methods utilized for this study, the participants
from Germany and the UK may not be repre-
sentative of patients with T2DM in each target
country. In addition, as this study was specific
to Germany and the UK, the participants in this
sample were predominantly Caucasian (93.5%).
There might be cultural or pathophysiological
differences among racial or ethnic groups, such
as Asians, that could influence preference for
treatment. The results of this study might not
be generalizable to other racial or ethnic groups.
Liraglutide QD and exenatide QW were selected
for comparison in this study because liraglutide
QD is a common T2DM treatment that is used
on a once-daily basis and exenatide QW, as well
as being the first once-weekly T2DM treatment
to be placed on the market, is commonly used
in both countries. In addition, they reflect key
differences in GLP1-RA treatments with differ-
ent side effects and regimens. The attributes
from these two specific GLP-1RA treatments
were included in this survey. However, the
outcomes from this study may not be general-
izable to other GPL-1RA treatments with dif-
ferent attributes which may be available in
other countries. Attributes included in the sur-
vey were limited to concepts that differed across
GLP1-RAs and that were found to be important
to patients. However, there may be other
aspects of treatment that could influence pref-
erence for treatment, such as out-of-pocket cost
or effects on overall health-related quality of
life. Thus, these results may not reflect market
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share for these treatments, as other attributes
may also influence treatment choice. Lastly,
this study solely assessed attribute importance
and treatment preferences by country. Exami-
nation of the influence of other sample char-
acteristics, such as age and treatment
experience (exenatide QW, liraglutide QD,
insulin, etc.), are areas for future research.
CONCLUSIONS
This study found that the most influential dri-
vers of treatment preference for GLP-1RAs were
efficacy, side effects, dosing frequency, and
required preparation among GLP-1RA injec-
tion-experienced T2DM patients in Germany
and the UK. Preference elicitation can promote
patient-centered care as well as inform new
generations of T2DM treatments, which can
lead to improved patient medication accep-
tance, adherence, and patient health outcomes.
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